Biodel Inc (NASDAQ:BIOD)

CAPS Rating: 3 out of 5

A specialty pharmaceutical company, which focused on the development and commercialization of innovative treatments for endocrine disorders such as diabetes and osteoporosis.

Results 1 - 20 of 29 : 1 2 Next »

Recs

0
Member Avatar TerryHoodSr (56.74) Submitted: 4/21/2014 10:28:58 AM : Outperform Start Price: $2.00 BIOD Score: -14.77

biotech spec, buy at $2, analyst target $6, rate 1.8

Recs

0
Member Avatar TerryFool (< 20) Submitted: 4/21/2014 8:05:51 AM : Outperform Start Price: $2.00 BIOD Score: -14.77

SPEC BUY@ 2.00 TP 6 CAPS 5

Recs

0
Member Avatar Haugurafpeningum (35.78) Submitted: 1/14/2014 11:56:01 PM : Outperform Start Price: $3.01 BIOD Score: -49.24

Plasm 10

Recs

0
Member Avatar line70day (< 20) Submitted: 12/16/2013 1:54:31 PM : Underperform Start Price: $2.19 BIOD Score: +29.72

Involved in reverse split must work under new Co. rules needs FDA & NDA approval Top line results from its phase 1 clincal trial of two insulins analig-based formulations 228 & 250 in trial both meet Co. expections .Co. has not made any money

Recs

0
Member Avatar bargain123 (36.37) Submitted: 11/25/2013 7:38:00 PM : Outperform Start Price: $2.26 BIOD Score: -31.44

it's kind of a interesting space,I believe, they are doing a hot research at the right time, when the world is getting overpopulated with diabetics and obese people, This is one of my ultra cheap speculative plays that is really hard to ignore.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 11/17/2013 6:39:15 PM : Outperform Start Price: $2.17 BIOD Score: -28.36

bman insider

Recs

0
Member Avatar SmartAce (99.86) Submitted: 10/8/2013 2:35:55 PM : Outperform Start Price: $3.08 BIOD Score: -60.87

This case just remained interesting.

Recs

0
Member Avatar donp8 (< 20) Submitted: 9/22/2013 10:00:21 PM : Outperform Start Price: $3.30 BIOD Score: -63.20

Future is bright.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 9/6/2013 11:38:51 AM : Outperform Start Price: $5.05 BIOD Score: -84.94

BIOD-123 (an ultra rapid acting insulin analog) trial results should be reported in next 2 weeks. Lots of buying coming in now when many biorunup investors should be exiting may be a tell for positive trial results.

Recs

0
Member Avatar T206 (71.81) Submitted: 9/3/2013 2:01:12 PM : Outperform Start Price: $4.77 BIOD Score: -84.72

Caps

Recs

0
Member Avatar eat251heart (< 20) Submitted: 5/29/2013 10:36:17 AM : Outperform Start Price: $3.75 BIOD Score: -73.71

helping folks live more comfortably in this aging game is key.

Recs

0
Member Avatar gip104 (< 20) Submitted: 5/29/2013 7:50:23 AM : Outperform Start Price: $3.78 BIOD Score: -73.74

i have a gut feeling about this!!!

Recs

5
Member Avatar zzlangerhans (99.77) Submitted: 5/20/2013 7:27:37 AM : Outperform Start Price: $3.11 BIOD Score: -63.22

I would have loved to write about Biodel back in December when I first flagged them as an outperformer in December, or in February when I bought 5000 shares at 2.65. Unfortunately I couldn't because of the arbitrary "liquidity" restrictions in CAPS that make many of my trades unrecordable here. As always, if you want the full story follow me on Twitter.

Basically, Biodel is a former high flier in the speculative diabetes sector that was brought low in 2008 when their developmental ultra rapid-acting injectable insulin Linjeta failed a phase III trial in type I diabetes. The company pursued a doomed strategy of selectively excluding the data they didn't like and submitting the NDA anyway, which the FDA appropriately rejected. That poor strategic decision cost the company tens of millions in cash and two years of time, and the FDA was validated when the company abandoned the Linjeta formulation rather than pursuing additional phase III trials. The share price was pressured further in 2011 and 2012 with failure of the next generation of ultrafast insulins, dilutive financings, and a reverse split. By the end of 2012 there were low trading volumes and absolutely no interest in the stock.

Those situations happen to be a specialty of mine. Once a stock is in my database, it stays there until buyout or bankruptcy and I faithful review it every three months. While Biodel had more than their share of bad outcomes, bad luck, and bad decisions in recent years, the fact remains that they have substantial expertise in development of ultrafast insulins and are absolutely not a scam outfit. Therefore, when I saw a market cap of 34M in December with a liquid asset balance of 39M I knew I needed to look for a bottom very carefully. I almost missed my opportunity when the share price jumped in January with positive phase I data for ultrafast insulin candidate BIOD-250. Fortunately for me, the results attracted little interest and I was able to get my 5000 shares at 2.65 on a slight pullback. Unfortunately for me, I didn't carry out my plan to double my position before the recent sharp ascent.

The significant upcoming catalyst for Biodel is topline results from the phase II trial of ultrafast insulin BIOD-123 expected in Q3, but the company has made progress with BIOD-250 as previously mentioned as well as BIOD-531 ultrafast concentrated insulin which is still preclinical. The market cap has now risen to 44M but cash is 28M and quarterly burn is well-controlled at 5-6M. I believe there's a high likelihood that the company will report positive results from the phase II trial and begin to draw substantial interest back to the stock, so I'll hopefully buck my poor record with binary catalysts when I hold through the data.

Recs

0
Member Avatar p1a5244 (54.72) Submitted: 9/18/2011 11:19:12 PM : Outperform Start Price: $4.84 BIOD Score: -130.76

9/18/11 Options Predictor Rank #27. P/C Ratio 0.053 and Call Sizzle 3.477.

Recs

0
Member Avatar MotleyNYSE (< 20) Submitted: 3/18/2011 10:48:46 AM : Outperform Start Price: $8.76 BIOD Score: -135.71

This will outperform only if they receive FDA approval. Otherwise, this stock will die out like MannKind

Recs

0
Member Avatar Br0oklyn (< 20) Submitted: 1/20/2011 7:59:11 AM : Outperform Start Price: $9.08 BIOD Score: -137.06

It develops its product candidates by applying its formulation technologies to existing drugs.

Recs

0
Member Avatar ExtremesTracker (45.63) Submitted: 12/7/2010 6:11:40 PM : Outperform Start Price: $7.12 BIOD Score: -137.96

picks source: zzlangerhans
as of 12/7/2010, these were the 5 most underperformed designated "top picks" by zz. these are the 5 picks (out 7 top picks):
alny,idra,rtix,biod,bdsi
No due diligence performed, these are hail marys that atleast a couple may possibly be insane multi baggers potentially
Very risky.

Recs

0
Member Avatar copydog1981 (< 20) Submitted: 10/8/2010 5:12:17 AM : Underperform Start Price: $18.08 BIOD Score: +163.03

They have some problems with the data of India.
So the best for the company that the FDA gives them a bit more time. Otherwist I don't see a approval

Recs

0
Member Avatar julianna8 (< 20) Submitted: 10/4/2010 10:51:37 AM : Outperform Start Price: $18.84 BIOD Score: -166.25

BUYBUYBUY!!!

Recs

4
Member Avatar BioInvestor217 (< 20) Submitted: 9/29/2010 12:08:15 AM : Outperform Start Price: $20.56 BIOD Score: -166.76

BIOD has quietly developed an improved mixed insulin product compatible with Lantus, which would allow the “holy grail” combination fast-acting/long acting insulin to be created. They are a top pick with an FDA review date of October 30th. Price estimate by that date of $7.00-$7.50. Once approved their insulin drug would revolutionize treatment of diabetes and will be targeting a massive market. Clinical tests and trials look good, overall very good outlook.

Results 1 - 20 of 29 : 1 2 Next »

Featured Broker Partners


Advertisement